SEPTInvestingStart Free

LTGO SCHEDULE 13D: SEC filing

Foresite Capital entities and James B. Tananbaum

Filed with the SEC on · accession 0001104659-26-097980

LTGO filed a SCHEDULE 13D (schedule 13d) with the SEC on Aug 17, 2026. Foresite Capital entities and James B. Tananbaum filed a joint filing agreement as an exhibit to a Schedule 13D regarding their position in Latigo Biotherapeutics common stock. The stock moved -1.0% by the first close after the filing.

Summary of the filing

Foresite Capital entities and James B. Tananbaum filed a joint filing agreement as an exhibit to a Schedule 13D regarding their position in Latigo Biotherapeutics common stock. The exhibit only establishes the agreement to file jointly and does not disclose ownership details or intentions.

For details, click here →

Key details

Reporting person / filerForesite Capital Fund VI LP
General partner of foresite capital fund vi lpForesite Capital Management VI, LLC
Reporting person / filerForesite Capital Fund V, L.P.
General partner of foresite capital fund v, l.p.Foresite Capital Management V, LLC
Reporting person / filerForesite Capital Opportunity Fund V, L.P.
General partner of foresite capital opportunity fund v, l.p.Foresite Capital Opportunity Management V, LLC
Issuer of the common stock to which the schedule 13d relatesLatigo Biotherapeutics, Inc.
Managing member, foresite capital managementJames B. Tananbaum

How LTGO stock reacted

Close before

$19.49

Aug 14, 2026

First close after

-0.97%

$19.30

5 trading days

+14.78%

$22.37

Since filing

-35.35%

$12.60

✦ Ask GOAX AI about this filing — what it means for LTGO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for LTGO?

Click here

Frequently asked questions

What did LTGO file with the SEC on Aug 17, 2026?

LTGO filed a SCHEDULE 13D (SEC filing). Foresite Capital entities and James B. Tananbaum filed a joint filing agreement as an exhibit to a Schedule 13D regarding their position in Latigo Biotherapeutics common stock. The exhibit only establishes the agreement to file jointly and does not disclose ownership details or intentions.

How do I read a SCHEDULE 13D?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D (schedule 13d): A report the company filed with the SEC (the US market regulator).

How did LTGO stock react to this filing?

LTGO closed at $19.49 before the filing and $19.30 on Aug 17, 2026 (-0.97%). Five trading days later: $22.37 (+14.78%).

Other LTGO SEC filings

Get alerts when LTGO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
LTGO overviewLTGO analysisLTGO newsLatest SEC filings